Table 1.
Univariate Analysis of Overall Survival Determinants in the Development Cohort
| Variable | n | Median | 95% CI | Log-rank |
|---|---|---|---|---|
| Age | ||||
| <70 y | 284 | 13.2 | 11.6–15.6 | 0.02 |
| ≥70 y | 117 | 10.9 | 8.8–11.7 | |
| Sex | ||||
| Male | 286 | 12.5 | 10.1–14.5 | 0.81 |
| Female | 115 | 12.3 | 10.8–14.2 | |
| ECOG performance status | ||||
| 0–1 | 266 | 16.0 | 14.1–18.1 | <10–4 |
| ≥2 | 135 | 7.9 | 6.7–9.3 | |
| Disease stage | ||||
| Nonmetastatic | 137 | 24.1 | 19.0–30.1 | <10–4 |
| IV | 264 | 9.2 | 8.4–10.1 | |
| Mixed histology | ||||
| No | 280 | 11.8 | 10.8–13.9 | 0.58 |
| Yes | 21 | 16.7 | 6.8–25.4 | |
| Charlson-Deyo score | ||||
| 0–1 | 234 | 13.2 | 11.2–15.2 | 0.20 |
| ≥ 2 | 162 | 11.1 | 9.3–12.9 | |
| Laterality | ||||
| Bilateral | 146 | 10.1 | 8.8–11.8 | < 0.01 |
| Median | 28 | 11.4 | 6.7–20.5 | |
| Unilateral | 225 | 14.4 | 11.8–17.1 | |
| BMI | ||||
| Underweight | 29 | 7.8 | 6.3–14.5 | 0.43 |
| Normal weight | 188 | 11.7 | 10.1–14.8 | |
| Overweight | 124 | 13.9 | 10.8–16.3 | |
| Obese | 46 | 14.1 | 9.2–17.8 | |
| Liver metastases | ||||
| No | 280 | 16.1 | 14.1–17.9 | 10–4 |
| Yes | 121 | 8.0 | 7.1–8.8 | |
| Neutrophils-to-lymphocytes ratio | ||||
| <4 | 202 | 15.6 | 12.8–18.3 | <10–4 |
| ≥4 | 194 | 10.1 | 9.2–11.8 | |
| Alkaline phosphatases (UI/L) | ||||
| 312 | 14.4 | 12.5–16.3 | <10–4 | |
| ≥130 | 82 | 7.9 | 6.6–9.3 | |
| Lactate dehydrogenase (UI/L) | ||||
| <220 | 76 | 17.7 | 13.5–22.0 | <0.01 |
| ≥220 | 303 | 11.6 | 10.0–13.0 | |
| Neuron-specific enolase (ng/mL) | ||||
| <12.5 | 26 | 24.9 | 14.1–49.3 | <0.01 |
| ≥12.5 | 335 | 11.7 | 10.3–13.5 | |
| Serum sodium (mmol/L) | ||||
| <135 | 93 | 9.5 | 7.7–11.6 | 0.01 |
| ≥135 | 303 | 13.5 | 11.6–15.7 | |
| Bicarbonates (mmol/L) | ||||
| <20 | 21 | 14.2 | 7.8–28.6 | 0.24 |
| ≥20 | 373 | 12.3 | 10.8–13.9 | |
| Albumin (g/L) | ||||
| ≥35 | 338 | 13.8 | 11.8–15.6 | <10–4 |
| <35 | 55 | 8.0 | 6.8–9.9 | |
| C-reactive protein (mg/L) | ||||
| ≤10 | 116 | 14.7 | 11.6–17.6 | <10–4 |
| >10 | 131 | 8.8 | 8.0–10.5 | |
| Glasgow prognostic score | ||||
| 0 | 112 | 15.9 | 11.8–17.7 | <10–4 |
| 1 | 97 | 10.5 | 8.6–13.5 | |
| 2 | 36 | 7.3 | 5.8–8.4 | |
| First-line chemotherapy | ||||
| PCDE | 111 | 17.4 | 14.4–23.0 | <10–4 |
| etoposide - platinum | 290 | 10.9 | 9.6–12.3 | |
| Thoracic radiotherapy | ||||
| Yes | 119 | 23.4 | 18.9–28.6 | <10–4 |
| No | 282 | 9.3 | 8.4–10.4 | |
| Surgery | ||||
| Yes | 17 | 49.3 | 16.4–NR | <10–3 |
| No | 384 | 11.7 | 10.3–13.2 | |
| Prophylactic cranial irradiation | ||||
| Yes | 168 | 20.4 | 17.8–25.0 | <10–4 |
| No | 232 | 8.4 | 7.5–9.6 | |
| Period of inclusion | ||||
| 2000–2004 | 73 | 14.5 | 11.2–17.4 | 0.13 |
| 2005–2009 | 93 | 13.8 | 10.0–17.8 | |
| 2010–2014 | 130 | 11.5 | 9.6–13.5 | |
| 2015–2019 | 105 | 10.8 | 8.4–13.9 |
PCDE, cisplatin–etoposide–4' epidoxorubin and cyclophosphamide; BMI, body mass index; NR, not reached; ECOG, Eastern Cooperative Oncology Group; CI, confidence interval.